Cano Health (CANO) Stock Forecast, Price Target & Predictions


OverviewOwnershipChartTranscripts

CANO Stock Forecast


Cano Health stock forecast is as follows: an average price target of $6.42 (represents a 1505.00% upside from CANO’s last price of $0.40) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CANO Price Target


The average price target for Cano Health (CANO) is $6.42 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $1.25. This represents a potential 1505.00% upside from CANO's last price of $0.40.

CANO Analyst Ratings


Buy

According to 3 Wall Street analysts, Cano Health's rating consensus is 'Buy'. The analyst rating breakdown for CANO stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cano Health Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 06, 2023-UBS$1.25$1.1013.64%212.50%
Nov 16, 2022-Citigroup$5.00$2.04144.79%1150.00%
May 10, 2022Jason CassorlaCitigroup$8.00$4.1393.94%1900.00%
Apr 20, 2022-UBS$15.00$5.16190.70%3650.00%
Mar 18, 2022Gary TaylorCowen & Co.$13.00$6.9985.98%3150.00%
Jan 14, 2022Jason CassorlaCitigroup$12.00$6.5184.33%2900.00%
Row per page
Go to

The latest Cano Health stock forecast, released on Jan 06, 2023 by UBS company, set a price target of $1.25, which represents a 13.64% increase from the stock price at the time of the forecast ($1.10), and a 212.50% increase from CANO last price ($0.40).

Cano Health Price Target by Period


1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.40$0.40$0.40
Upside/Downside-100.00%-100.00%-100.00%

In the current month, the average price target of Cano Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cano Health's last price of $0.40. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Jan 06, 2023UBS-NeutralDowngrade
Nov 16, 2022CitigroupBuyBuyHold
Jun 24, 2022Raymond James-OutperformInitialise
May 10, 2022CitigroupBuyBuyHold
Row per page
Go to

Cano Health's last stock rating was published by UBS on Jan 06, 2023. The company Downgrade its CANO rating from "null" to "Neutral".

Cano Health Financial Forecast


Cano Health Revenue Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Sep 21Jun 21
Revenue----$788.07M$766.75M$866.91M$704.34M$526.80M$393.16M
Avg Forecast$1.73B$1.53B$1.34B$710.55M$759.84M$828.43M$826.34M$666.03M$435.67M$306.85M
High Forecast$1.76B$1.57B$1.37B$711.00M$772.00M$845.87M$843.74M$680.06M$444.84M$313.31M
Low Forecast$1.71B$1.52B$1.33B$710.10M$742.40M$820.37M$818.30M$659.55M$431.43M$303.86M
# Analysts--12311111
Surprise %----1.04%0.93%1.05%1.06%1.21%1.28%

Cano Health's average Quarter revenue forecast for Dec 23 based on 2 analysts is $710.55M, with a low forecast of $710.10M, and a high forecast of $711.00M. CANO's average Quarter revenue forecast represents a -9.84% decrease compared to the company's last Quarter revenue of $788.07M (Sep 23).

Cano Health EBITDA Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Sep 21Jun 21
# Analysts--12311111
EBITDA----$-65.86M$-142.09M$-5.88M$11.29M$-33.60M$25.12M
Avg Forecast$38.65M$34.35M$30.06M$15.92M$17.02M$18.56M$18.51M$27.79M$-36.96M$6.87M
High Forecast$39.46M$35.08M$30.69M$15.93M$17.29M$18.95M$18.90M$33.35M$-29.57M$7.02M
Low Forecast$38.27M$34.02M$29.77M$15.91M$16.63M$18.38M$18.33M$22.23M$-44.36M$6.81M
Surprise %-----3.87%-7.66%-0.32%0.41%0.91%3.65%

1 analysts predict CANO's average Quarter EBITDA for Mar 23 to be $18.51M, with a high of $18.90M and a low of $18.33M. This is 63.89% upper than Cano Health's previous annual EBITDA (Mar 22) of $11.29M.

Cano Health Net Income Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Sep 21Jun 21
# Analysts--12311111
Net Income----$-260.49M$-140.75M$-28.15M$-85.00K$-67.13M$9.48M
Avg Forecast$813.63M$708.69M$832.13M$-100.29M$-121.41M$-47.51M$-73.90M$1.22M$-73.84M$-38.71M
High Forecast$25.13B$21.89B$25.70B$-5.81B$-7.39B$-1.47B$-2.28B$1.46M$-59.07M$-1.20B
Low Forecast$43.42B$37.82B$44.40B$-10.03B$-12.14B$-2.53B$-3.94B$975.52K$-88.61M$-2.07B
Surprise %----2.15%2.96%0.38%-0.07%0.91%-0.24%

Cano Health's average Quarter net income forecast for Sep 21 is $-73.84M, with a range of $-88.61M to $-59.07M. CANO's average Quarter net income forecast represents a -878.92% decrease compared to the company's last Quarter net income of $9.48M (Jun 21).

Cano Health SG&A Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Sep 21Jun 21
# Analysts--12311111
SG&A----$80.82M$99.42M$96.47M$96.59M$75.93M$46.57M
Avg Forecast$258.60M$229.87M$201.13M$106.51M$113.90M$124.18M$123.87M$178.45M$83.52M$46.00M
High Forecast$264.05M$234.71M$205.37M$106.58M$115.72M$126.79M$126.48M$214.14M$100.22M$46.96M
Low Forecast$256.08M$227.63M$199.18M$106.44M$111.28M$122.97M$122.66M$142.76M$66.81M$45.55M
Surprise %----0.71%0.80%0.78%0.54%0.91%1.01%

Cano Health's average Quarter SG&A projection for Dec 23 is $106.51M, based on 2 Wall Street analysts, with a range of $106.44M to $106.58M. The forecast indicates a 31.79% rise compared to CANO last annual SG&A of $80.82M (Sep 23).

Cano Health EPS Forecast

Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Mar 22Sep 21Jun 21
# Analysts--12311111
EPS----$-91.87$-0.00$-0.12$-0.00$-0.09$0.06
Avg Forecast$1.54$1.34$1.58$-0.19$-0.23$-0.09$-0.14$-0.10$-0.00$-0.07
High Forecast$47.61$41.47$48.69$-11.00$-14.00$-2.78$-4.32$-3.09$-0.05$-2.27
Low Forecast$82.25$71.64$84.12$-19.00$-23.00$-4.80$-7.47$-5.34$-0.08$-3.91
Surprise %----399.43%0.01%0.86%0.00%59.60%-0.82%

According to 1 Wall Street analysts, Cano Health's projected average Quarter EPS for Sep 21 is $-0.00, with a low estimate of $-0.08 and a high estimate of $-0.05. This represents a -102.52% decrease compared to CANO previous annual EPS of $0.06 (Jun 21).

Cano Health Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TOIOncology Institute$0.28$8.002757.14%Buy
CANOCano Health$2.30$6.42179.13%Buy
ACHCAcadia Healthcare Company$42.33$82.3394.50%Buy
AGLagilon health$2.67$4.4064.79%Buy
EHABEnhabit$7.63$10.2534.34%Hold
BKDBrookdale Senior Living$6.24$7.5020.19%Buy
AMEHAstrana Health$40.82$48.5018.81%Buy
INNVInnovAge$5.90$6.8015.25%Hold
SEMSelect Medical$36.51$40.009.56%Buy
PNTGPennant Group$32.38$34.677.07%Buy
UHSUniversal Health Services$208.83$208.47-0.17%Hold
ENSGEnsign Group$153.39$148.20-3.38%Buy
THCTenet Healthcare$162.38$128.60-20.80%Buy

CANO Forecast FAQ


Yes, according to 3 Wall Street analysts, Cano Health (CANO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of CANO's total ratings.

Cano Health (CANO) average price target is $6.42 with a range of $1.25 to $13, implying a 1505.00% from its last price of $0.4. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for CANO stock, the company can go up by 1505.00% (from the last price of $0.4 to the average price target of $6.42), up by 3150.00% based on the highest stock price target, and up by 212.50% based on the lowest stock price target.

CANO's average twelve months analyst stock price target of $6.42 supports the claim that Cano Health can reach $1 in the near future.

CANO's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $3.13B (high $3.17B, low $3.09B), average EBITDA is $70.01M (high $71.07M, low $69.25M), average net income is $-343M (high $-16.946B, low $-28.648B), average SG&A $468.46M (high $475.57M, low $463.36M), and average EPS is $-0.65 (high $-32.104, low $-54.273).

In terms of the last quarterly report (Sep 2023), Cano Health's revenue was $788.07M, beating the average analysts' forecast of $759.84M by 3.72%. The company's EBITDA was $-65.859M, missing the average prediction of $17.02M by -486.91%. Cano Health's net income was $-260M, beating the average estimation of $-121M by 114.56%. The company's SG&A was $80.82M, missing the average forecast of $113.9M by -29.04%. Lastly, the company's EPS was $-91.87, beating the average prediction of $-0.23 by 39843.48%